Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.50+0.10 (+1.56%)
Close on Nov 17, 2026Market cap $65.25MP/E –Yield –
Atara Biotherapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Atara Biotherapeutics's revenue for the twelve months ending Jun 30, 2026 was $6.19M, down 96.7% year over year. For fiscal 2025 it was $120.77M, down 6.3% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.77M | -6.3% |
| FY2024 | Dec 31, 2024 | $128.94M | +1404.0% |
| FY2023 | Dec 31, 2023 | $8.57M | -86.5% |
| FY2022 | Dec 31, 2022 | $63.57M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $630.00K | -96.4% |
| Q1 FY2026 | Mar 31, 2026 | $516.00K | -99.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.60M | -95.1% |
| Q3 FY2025 | Sep 30, 2025 | $3.45M | -91.4% |
| Q2 FY2025 | Jun 30, 2025 | $17.58M | -38.6% |
| Q1 FY2025 | Mar 31, 2025 | $98.15M | +258.8% |
| Q4 FY2024 | Dec 31, 2024 | $32.75M | +670.3% |
| Q3 FY2024 | Sep 30, 2024 | $40.19M | +1779.8% |
| Q2 FY2024 | Jun 30, 2024 | $28.64M | +2892.7% |
| Q1 FY2024 | Mar 31, 2024 | $27.36M | +2131.4% |
| Q4 FY2023 | Dec 31, 2023 | $4.25M | +1824.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.14M | -52.1% |
| Q2 FY2023 | Jun 30, 2023 | $957.00K | -98.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.23M | -83.2% |
| Q4 FY2022 | Dec 31, 2022 | $221.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $4.46M | – |
| Q2 FY2022 | Jun 30, 2022 | $51.58M | – |
| Q1 FY2022 | Mar 31, 2022 | $7.31M | – |
See a number that looks wrong?